Ocuphire Pharma Investor Update

7 Ocuphire Pipeline & Clinical Milestones Multiple Phase 3 & Phase 2 Clinical Data Readouts Anticipated this Year Indication Reversal of Mydriasis (RM) Presbyopia (P) Dim Light or Night Vision Disturbances (NVD) Diabetic Retinopathy (DR)/ Macular Edema (DME) DME or Wet Age- Related Macular Degeneration (WAMD) Product Candidate NyxolⓇ Eye Drop Nyxol® Eye Drop Nyxol® + Low-Dose (0.4%) Pilocarpine Eye Drops NyxolⓇ Eye Drop APX3330 Oral Pill APX2009 (Intravitreal or Local Delivery) Pre-clinical Phase 1 Phase 2 VEGA-1 ✓ Phase 3 ✓ MIRA-3 MIRA-2 ★ MIRA-4 Regulatory Approval ★LYNX-1 ★ZETA-1 Recent Positive Trial Data Ongoing Trial Note: 0.75% Nyxol (Phentolamine Ophthalmic Solution) is the same as 1% Nyxol (Phentolamine Mesylate Ophthalmic Solution) Anticipated Milestones Reported MIRA-3 Phase 3 data in Q1 2022 (n=368) MIRA-4 Pediatric safety study data expected in 2Q 2022 (n=23) VEGA Phase 3 program planned to initiate in mid-2022 LYNX-1 Phase 3 data expected in 2Q 2022 (n=145) ZETA-1 Phase 2b data expected in 2H22 (n=103) Seeking partner funding for IND enabling studies and further development Ocuphire PHARMA

View entire presentation